Forte Biosciences, Inc. — Director's Dealing 2018

Mar 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2018-03-01

Reporting Person: Duvall Martin J (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-01	Employee Stock Option (right to buy)	$11.19	A	150000	Acquired	2028-02-29	Common Stock (150000)	Direct

Footnotes

F1: 1/4th of the shares vest one year after 3/01/2018; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 3/01/2018.